Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat.

By H. Grundmann, M. Aires-de-Sousa, J. Boyce, E. Tiemersma. The Lancet, 2006

1,176 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. (2007, background): “Although the emergence of multidrug-resistant (MDR) Gram-positive bacteria has been a public health issue, a handful of novel antibiotics have been developed and recently approved for the treatment of infections caused by these organisms.(2) – 5 A major challenge has arisen, however, regarding the t”
The evolution of Staphylococcus aureus. (2008, methodology): “The four ype V J1 (377 bp) (Milheirico et al., 2007b). jection drug users, would be classified as SCCmec type VI with the method of Ito et al. nosocomial infections worldwide (Grundmann et al., 2006).”
Action and resistance mechanisms of antibiotics: A guide for clinicians (2017, background): “D-alanyl-alanine is changed to D-alanyl-lactate as a result of which glycopeptides do not cross link with them, hence resistance to them develops.[4,5] E.”
Plasma medicine: an introductory review (2009, neutral): “Amongst envisaged applications are • Hospital hygiene : Particularly, the growth of resistant bacteria (e.g. MRSA) poses a problem that requires fast and efﬁcient sterilization [38].”
Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology (2018, background): “nated, this strain began to decline in the 1970s to 1980s (510).”